NON-FINAL ACTION - MAILED
final action
on 15 Dec 2024
Last Applicant/ Owned by
1 Cavendish Place London W1G 0QF
GB
Serial Number
79406335 filed on 22nd Apr 2024
Registration Number
N/A
Correspondent Address
Filing Basis
1. filing basis filed as 66 a
Disclaimer
NO DATA
Logo Mark Trademark Information
Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and pharmaceutical research services; scientific research for medical purposes; research, inspection, testing, development and evaluation in the field of medicine and disease; research, inspection, testing, development and evaluation of pharmaceutical and veterinary pr Read More
Classification Information
Class [042]
Computer & Software Services & Scientific Services
Scientific and technological services and research and design relating thereto; industrial analysis and research services; medical and pharmaceutical research services; scientific research for medical purposes; research, inspection, testing, development and evaluation in the field of medicine and disease; research, inspection, testing, development and evaluation of pharmaceutical and veterinary preparations, products and drugs, sanitary preparations for medical purposes, and dietetic food and substances; clinical trials; information, advisory and consultancy services relating to all the aforesaid services.
First Use Date in General
N/A
First Use Date in Commerce
N/A
Class [005]
Pharmaceutical Products
Pharmaceutical and veterinary preparations; biopharmaceuticals; sanitary preparations for medical purposes; dietetic food and substances adapted for medical or veterinary use; pharmaceutical preparations and drugs for the treatment of rare and specialist diseases and conditions; pharmaceutical preparations and drugs for the treatment of orphan diseases; pharmaceutical preparations and drugs for the treatment of respiratory disorders; pharmaceutical preparations and drugs for the treatment of chronic obstructive pulmonary disease (COPD); pharmaceutical preparations and drugs for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD); pharmaceutical preparations and drugs namely bronchodilators and anti-asthma preparations; pharmaceutical preparations and drugs for the treatment of osteogenesis imperfecta (OI) (brittle bone syndrome); pharmaceutical preparations and drugs to improve bone density and treat bone weakness; pharmaceutical preparations and drugs for the treatment of bone-related diseases; pharmaceutical preparations and drugs for the treatment of bone disorders associated with low bone formation, low bone mineral density, low bone mineral content, low bone mass, or low bone strength; pharmaceutical preparations and drugs for the treatment of diseases or disorders associated with collagen mutations; pharmaceutical preparations and drugs for the treatment of obesity; pharmaceutical preparations and drugs for normalising testosterone levels; pharmaceutical preparations and drugs namely aromatase inhibitors (AIs); pharmaceutical preparations and drugs for treating hypogonadotrophic hypogonadism (HH); antibiotics; pharmaceutical preparations and drugs for the treatment of diseases mediated by α-1 antitrypsin deficiency (AATD); pharmaceutical preparations and drugs for the treatment of respiratory diseases; pharmaceutical preparations and drugs for the treatment or prophylaxis of inflammatory diseases and conditions; pharmaceutical preparations and drugs for the treatment or prevention of a symptom or complication attributable of a SARS-COV infection; pharmaceutical preparations and drugs for the treatment of COVID-19; pharmaceutical preparations and drugs for the treatment or prevention of fibrosis; pharmaceutical preparations and drugs for the treatment or prevention of graft rejection; pharmaceutical preparations and drugs for the treatment or prevention of graft versus host disease (GVHD); pharmaceutical preparations and drugs for the treatment or prevention of bronchiolitis obliterans syndrome (BOS); pharmaceutical preparations and drugs for the treatment of cancer; pharmaceutical preparations and drugs for the treatment of checkpoint inhibitor naïve cancer; pharmaceutical preparations and drugs for the treatment of cervical cancer; pharmaceutical preparations and drugs for the treatment of breast cancer; pharmaceutical preparations and drugs for the treatment of ovarian cancer; pharmaceutical preparations and drugs for the treatment of clear cell ovarian cancer; pharmaceutical preparations and drugs for the treatment of sarcoma; pharmaceutical preparations and drugs for the treatment of soft tissue sarcoma; pharmaceutical preparations and drugs for the treatment of de-differentiated liposarcoma sarcoma; pharmaceutical preparations and drugs for the treatment of germ cell tumours; pharmaceutical preparations and drugs for the treatment of testicular germ cell tumours; pharmaceutical preparations and drugs for the treatment of uveal melanomas; pharmaceutical preparations and drugs for the treatment of cancers with a high tumour mutational burden (TMB); pharmaceutical preparations and drugs for the treatment of microsatellite stable cancer; pharmaceutical preparations and drugs for the treatment of endometrial cancer; pharmaceutical preparations and drugs for the treatment of PVR positive cancer; pharmaceutical preparations and drugs for the treatment of TIGIT positive cancer; pharmaceutical preparations and drugs for the treatment of PD-L1 negative cancer; pharmaceutical preparations and drugs for the treatment of CD226 positive cancer; pharmaceutical preparations and drugs for the treatment of CD8 positive cancer; pharmaceutical preparations and drugs for the treatment of cancer involving reducing Tregs and promoting myeloid cell activation.
First Use Date in General
N/A
First Use Date in Commerce
N/A
Mark Details
Serial Number
No 79406335
Mark Type
No Service Mark
Attorney Docket Number
No
44D Filed
No
44D Current
No
44E filed
No
44E Current
No
66A Filed
Yes
66A Current
Yes
Current Basis
No
No Basis
No
Design Code(s)
26.17.09 -
Curved line(s), band(s) or bar(s)
Legal History
| Status Date | Action Taken |
|---|---|
| 05th Jan 2025 | REFUSAL PROCESSED BY IB |
| 15th Dec 2024 | REFUSAL PROCESSED BY MPU |
| 15th Dec 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| 01st Dec 2024 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| 29th Nov 2024 | NON-FINAL ACTION WRITTEN |
| 04th Nov 2024 | ASSIGNED TO EXAMINER |
| 11th Oct 2024 | APPLICATION FILING RECEIPT MAILED |
| 11th Oct 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| 10th Oct 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |